Bandung, Indonesia — Understanding how well our bodies are protected after COVID-19 vaccination or infection remains a critical question for public health. Dr. Agnes Rengga Indrati from the Department of Clinical Pathology, Faculty of Medicine, Universitas Padjadjaran led a study to assess the protection level provided by S-RBD SARS-CoV-2 Immunoglobulin G (IgG) antibodies using a chemiluminescent immunoassay.

The S-RBD antibodies target the virus’s spike protein receptor-binding domain, blocking it from attaching to human cells. Measuring these antibodies offers an important tool for gauging immunity, especially in populations at higher risk.

In this research, samples from participants were analyzed to determine antibody concentrations and compare them with established protection thresholds. The findings provided clear data on what antibody levels correspond to a likely protective effect against COVID-19. This information is crucial for healthcare providers to guide booster vaccination schedules, particularly for vulnerable groups such as the elderly or immunocompromised.

By standardizing how antibody levels are interpreted, the study supports more precise public health decisions, ensuring resources are allocated efficiently and effectively. It also empowers individuals and communities with clearer understanding of their immunity status.

This work contributes to SDG 3: Good Health and Well-being, reinforcing Universitas Padjadjaran’s role in translating laboratory science into actionable health strategies that have both local and global relevance — and strengthening the university’s position in the Times Higher Education Impact Rankings.